Clinical Development of Angiogenesis Inhibitors to Vascular Endothelial Growth Factor and Its Receptors as Cancer Therapeutics

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|2|2|135-156

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.2, Iss.2, 2002-06, pp. : 135-156

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Antiangiogenic agents targeting vascular endothelial growth factor and its receptors in clinical development

By Sepp-Lorenzino Laura   Thomas Kenneth A  

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 10, 2002-10 ,pp. : 1447-1465

Informa Healthcare

Access to resources Recommend Favorite

Development of Vascular Endothelial Growth Factor Receptor (VEGFR) Kinase Inhibitors as Anti-Angiogenic Agents in Cancer Therapy

By  

Current Medicinal Chemistry, Vol. 11, Iss. 6, 2004-03 ,pp. : 731-745

Bentham Science Publishers

Access to resources Recommend Favorite

Vascular endothelial growth factor tyrosine kinase inhibitors

By  

Expert Opinion on Therapeutic Patents, Vol. 14, Iss. 6, 2004-06 ,pp. : 921-924

Informa Healthcare

Access to resources Recommend Favorite

Novel Therapeutic Approaches Targeting Vascular Endothelial Growth Factor and its Receptors in Haematological Malignancies

By  

Current Cancer Drug Targets, Vol. 5, Iss. 8, 2005-12 ,pp. : 573-578

Bentham Science Publishers

Access to resources Recommend Favorite

The Critical Role of Vascular Endothelial Growth Factor in Tumor Angiogenesis

By  

Current Cancer Drug Targets, Vol. 12, Iss. 1, 2012-01 ,pp. : 23-43

Bentham Science Publishers

Access to resources Recommend Favorite